IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
The U.S. FDA issued a Form 483 with five observations
Facility designed to advance the next generation of imaging systems
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Subscribe To Our Newsletter & Stay Updated
